小结
定义
病史和体格检查
关键诊断因素
- underlying primary headache disorder
- headache on ≥15 days per month
- overuse of acute headache medication for >3 months
其他诊断因素
- normal neurologic exam
- absence of red flag symptoms and/or signs
危险因素
- migraine as the underlying primary headache disorder
- female sex
- use of opioid, barbiturate, triptan, or ergot derivative
- anxiety and/or depression
- chronic musculoskeletal disease
- chronic gastrointestinal disease
- low-level education
诊断性检查
首要检查
- clinical diagnosis
需考虑的检查
- MRI brain
- CT brain
- CRP/erythrocyte sedimentation rate (ESR)
- lumbar puncture (LP)
- cerebrospinal fluid (CSF) culture
治疗流程
adults: uncomplicated
adults: complex
children and adolescents
撰稿人
作者
Sait Ashina, MD, FAHS
Director
BIDMC Comprehensive Headache Center
Beth Israel Deaconess Medical Center
Assistant Professor of Neurology and Anesthesia
Department of Neurology and Anesthesia
Critical Care and Pain Medicine
Harvard Medical School
Boston
MA
利益声明
SA declares that he has received fees for consulting from Allergan, AbbVie, Eli Lilly, Impel NeuroPharma, Linpharma, Lundbeck, Satsuma, and Theranica. He has received fees for teaching from Eli Lilly and Teva. He has received unrestricted research grants from AbbVie, Eli Lilly, and NINDS, paid to his hospital/institution. SA also serves as Associate Editor for the journals Neurology Reviews, Frontiers in Neurology, and BMC Neurology, and is an advisory board member for the Journal of Headache.
Hsiangkuo Yuan, MD, PhD
Associate Professor of Neurology
Department of Neurology
Director of Clinical Research
Jefferson Headache Center
Thomas Jefferson University
Philadelphia
PA
利益声明
HY declares that he has received a grant from the National Institutes of Health (reference R44NS115460). He has served as a site investigator for Teva, AbbVie, Trillen, and Thermaquil. He has also served on advisory boards or as a consultant for Silva, Clexio Biosciences, and Pfizer.
同行评议者
Benjamin Wakerley, FRCP, PhD
Consultant Neurologist
Headache Lead
University Hospital Birmingham NHS Foundation Trust
Honorary Clinical Associate Professor
University of Birmingham
Birmingham
UK
Divulgaciones
BW declares that he has received speaking fees from AbbVie. He is the founder of Ceftronics Ltd and a creator of the CEFREF headache app.
Alyssa Ann LeBel, MD
Director
Chronic Headache Program
Boston Children's Hospital
Associate Professor of Anesthesia
Harvard Medical School
Boston
MA
Divulgaciones
AAL declares that she has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
International Headache Society. 2018 International Headache Society international classification of headache disorders (ICHD), 3rd edition. 2018 [internet publication].Texto completo
Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. Nat Rev Dis Primers. 2023 Feb 2;9(1):5. Resumen
Diener HC, Antonaci F, Braschinsky M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020 Jul;27(7):1102-16.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Chronic primary headache disorder
- Idiopathic intracranial hypertension (pseudotumor cerebri)
- Spontaneous intracranial hypotension and/or cerebrospinal fluid (CSF) leak
Más DiferencialesGuías de práctica clínica
- European Academy of Neurology guideline on the management of medication-overuse headache
- International classification of headache disorders, 3rd edition
Más Guías de práctica clínicaInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad